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coBACKGROUND Catheter ablation is important for treatment of paroxysmal atrial ﬁbrillation (PAF). Limited animal
and human studies suggest a correlation between electrode-tissue contact and radiofrequency lesion generation.
OBJECTIVES The study sought to assess the safety and effectiveness of an irrigated, contact force (CF)-sensing
catheter in the treatment of drug refractory symptomatic PAF.
METHODS A prospective, multicenter, nonrandomized study was conducted. Enrollment criteria included: $3
symptomatic episodes of PAF within 6 months of enrollment and failure of $1 antiarrhythmic drug (Class I to IV).
Ablation included pulmonary vein isolation with conﬁrmed entrance block as procedural endpoint.
RESULTS A total of 172 patients were enrolled at 21 sites, where 161 patients had a study catheter inserted and 160
patients underwent radiofrequency application. Procedural-related serious adverse events occurring within 7 days of the
procedure included tamponade (n ¼ 4), pericarditis (n ¼ 3), heart block (n ¼ 1, prior to radiofrequency application), and
vascular access complications (n ¼ 4). By Kaplan-Meier analyses, 12-month freedom from atrial ﬁbrillation/atrial ﬂutter/
atrial tachycardia recurrence was 72.5%. The average CF per procedure was 17.9  9.4 g. When the CF employed was
between investigator selected working ranges $80% of the time during therapy, outcomes were 4.25 times more likely
to be successful (p ¼ 0.0054; 95% conﬁdence interval: 1.53 to 11.79).
CONCLUSIONS The SMART-AF trial demonstrated that this irrigated CF-sensing catheter is safe and effective for
the treatment of drug refractory symptomatic PAF, with no unanticipated device-related adverse events. The increased
percent of time within investigator-targeted CF ranges correlates with increased freedom from arrhythmia recurrence.
Stable CF during radiofrequency application increases the likelihood of 12-month success. (THERMOCOOL
SMARTTOUCH Catheter for Treatment of Symptomatic Paroxysmal Atrial Fibrillation; NCT01385202) (J Am Coll
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AND ACRONYMS
AAD = antiarrhythmic drug
AF = atrial ﬁbrillation
AFL = atrial ﬂutter
AT = atrial tachycardia
CF = contact force
CI = conﬁdence interval
KM = Kaplan-Meier
LA = left atrium/left atrial
PAF = paroxysmal atrial
ﬁbrillation
PV = pulmonary vein
QOL = quality of life
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648R adiofrequency catheter ablationtherapy is an important treatmentfor atrial ﬁbrillation (AF) (1). The
cornerstone of AF ablation involves crea-
tion of a series of lesions via resistive
heating encircling the pulmonary veins
(PV), isolating spontaneous ectopic beats
from the left atrium (LA) (2). Lesion forma-
tion is traditionally monitored as electrogram
diminution and impedance drop during
application. Missing from this procedure is
knowledge of electrode-to-tissue interaction.
Several in vivo and in vitro studies have
shown a correlation between electrode-tissue
contact and lesion generation (3,4). A recent
clinical study using a contact force (CF)–sensing catheter suggested that CF during ablation
correlates with clinical outcome in AF patients (5,6).SEE PAGE 657The CF catheter used in the present study was
developed using a small spring connecting the abla-
tion tip electrode to the catheter shaft with a magnetic
transmitter and sensors to measure microdeﬂection
of the spring (7,8). This system has a CF resolution
<1 g in bench testing (7,8). SMART-AF was conducted
to evaluate the safety and effectiveness of this
catheter during standard ablation procedures.
METHODS
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All patients enrolled in the study provided written
informed consent and each site assigned a sequential
identiﬁcation number.
STUDY DESIGN. The prospective, multicenter, non-
randomized clinical study was designed to evaluate
the safety and effectiveness of drug-refractory par-
oxysmal AF (PAF) ablation utilizing the ThermoCool
SmartTouch Catheter (Biosense Webster, Inc., Dia-
mond Bar, California) compared to predetermined
performance goals. The ablation catheter has been
described in detail elsewhere (7,8).
Patients were observed at 1, 3, 6, 9, and 12 months
post-ablation, with a 3-month blanking period for
anatomical and electrical remodeling of the LA. Elec-
trocardiograms were obtained at all follow-up visits.
Transtelephonic monitoring (PER900; Agility Cen-
tralized Research Service, Bannockburn, Illinois) was
performed during the 9-month post-blanking period.
Patients were required to transmit all symptomatic
cardiac episodes and to provide additional scheduled
transmissions irrespective of symptoms: weekly for
the ﬁrst 8 weeks, then monthly thereafter. An inde-
pendent safety monitoring committee reviewed and
adjudicated all adverse events.
STUDY POPULATION. Enrollment required at least 3
symptomatic AF episodes within the 6 months before
enrollment (1 AF episode documented within 1 year),
and nonresponse to at least 1 antiarrhythmic drug
(AAD) (Class I, Class III, or atrioventricular nodal
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649Study exclusion criteria were patients <18 years of
age, AF of more than 30 days in duration, ejection
fraction <40%, previous AF ablation, documented
LA thrombus, amiodarone therapy or coronary artery
bypass graft procedure in the previous 6 months,
New York Heart Association (NYHA) functional class
III or class IV, myocardial infarction within the pre-
vious 2 months, thromboembolic event in the pre-
vious 12 months, severe pulmonary disease, prior
valvular cardiac surgical procedure, presence of an
implanted cardioverter-deﬁbrillator, contraindication
to antiarrhythmic or anticoagulation medications, life
expectancy of <12 months, and LA $50 mm in the
parasternal long axis view.
CATHETER ABLATION. PV isolation with con-
ﬁrmation of entrance block was required (1).
Three-dimensional electroanatomical mapping was
performed using the Carto 3 System (Biosense
Webster, Inc.). Steerable sheath was used in 51.5% of
all procedures. CF measurements were sampled at
50 ms (20 Hz) intervals during radiofrequency appli-
cation. The PVs were isolated by a circumferential
lesion set. In the event of spontaneous or induced AF
and/or atrial ﬂutter (AFL), additional ablation was
allowed at the investigator discretion and included
LA linear lesions (roof line between both superior
PVs, mitral isthmus line between mitral annulus and
left inferior PV, or anterior line between the LA
roof and mitral annulus), ablation at sites with elec-
trogram fractionation, and cavotricuspid isthmus
ablation. Infusion of isoproterenol (#20 mg/min)
was recommended post-ablation to conﬁrm that all
AF foci had been identiﬁed, eliminated, or isolated.
After the initial procedure, patients were allowed up
to 2 repeat ablation procedures within 90 days of the
index procedure. At the discretion of the investigator,
a previously ineffective drug, at the same dose
or lower, could be continued during the effective-
ness evaluation period. Following ablation, anti-
coagulation with warfarin was required for the initial 3
months. Subsequent use of anticoagulation during the
effectiveness evaluation period followed current
guidelines (9).
ROLL-IN CASES AND CF WORKING RANGES. Each
investigator was required to recruit 1 to 2 “calibration
roll-in” subjects (at the investigator’s discretion),
in which investigators would calibrate their individual
tactile feel, catheter manipulation technique, and use
of other surrogate measures (e.g., electrogram signal,
impedance) during the procedure with the displayed
CF. During the calibration roll-in procedure(s), the
investigators selected the reference ranges based on
training. No working range was prescribed.At the end of the procedure, investigators reviewed
ofﬂine the CF measured during the roll-in case(s).
Investigators were then able to use the information to
conﬁgure the operating reference ranges for their
subsequent cases. The selection of working range
could change as investigators performed additional
cases in the study.
EFFECTIVENESS OUTCOMES. The effectiveness out-
come was freedom from documented symptomatic
AF/atrial tachycardia (AT)/AFL during the evaluation
period. AF/AT/AFL episodes of $30 s were considered
recurrent events. Per study protocol, patients with
absence of entrance block conﬁrmed in all PVs at the
end of the ablation procedure, repeat ablation after
Day 90, or changes in speciﬁed drug regimen post-
blanking also were considered treatment failures,
even if the patient remained free from symptomatic
AF/AT/AFL.
SAFETY OUTCOMES. Major adverse events were de-
ﬁned as procedure- or device-related serious adverse
events (e.g., tamponade, pericarditis, pericardial effu-
sion, perforation), which occurred within 7 days fol-
lowing the ablation procedure, including PV stenosis
and atrioesophageal ﬁstula that occurred >7 days
post-procedure.
ADDITIONAL OUTCOMES. Additional patient-reported
outcomes included assessment of quality of life
(QOL) using the 36-item Short Form Health Survey
Version 2 (10) and the AF Symptom Frequency and
Severity Checklist (11). In addition, the effectiveness
outcome of freedom from AF/AT/AFL recurrences
post–initial ablation procedures and off Class I/III
AAD at 12 months follow-up visit also was analyzed
and summarized.
STATISTICAL METHODS. A Kaplan-Meier (KM)
curve was plotted for the time to ﬁrst AF/AT/AFL
recurrence following initial ablation procedures. The
probabilities of freedom from AF/AT/AFL recurrence
at each monthly follow-up time point post-blanking,
along with the corresponding 95% conﬁdence in-
tervals (CIs) using Greenwood’s formula, were pre-
sented. This analysis was stratiﬁed by the percentage
of time with CF within each investigator’s selected
ranges dichotomized at its median value of 80%.
The correlations of average CF and percentage of
time of CF $40 g, dichotomized at the median values,
with major adverse events and tamponade were
examined. The correlations of average CF and per-
centage of time of CF with investigator selected
ranges, dichotomized at the median value of 80%,
with freedom from AF/AFL/AT recurrence were
examined. Fisher exact test and logistic regression
Enrolled
N=172
Safety Cohort
N=161
Effectiveness
Cohort
N=122
Excluded (n=11)
Discontinued (n=1)
Roll-in (n=38)
FIGURE 1 Patient Flow Diagram
Disposition of subjects in the study. Excluded patients: enrolled
patients who never underwent insertion of the study catheter;
discontinued subjects: enrolled patients who had the study
catheter inserted but were not ablated; roll-in patients: the ﬁrst
1 or 2 enrolled patient(s) treated with the study catheter.
Natale et al. J A C C V O L . 6 4 , N O . 7 , 2 0 1 4
AF Ablation and Contact Force Sensing Catheter A U G U S T 1 9 , 2 0 1 4 : 6 4 7 – 5 6
650analyses were performed to test for signiﬁcant
associations. In the logistic regression analyses, sub-
jects with any major adverse events or tamponade
and subjects free from AF/AFL/AT recurrence were
treated as outcome and the CF measurements were
treated as independent variables. Forward selection
method was used to include the potential con-
founders of demographics, baseline characteristics,
and procedural parameters that were associated with
the outcome at p value <0.2 at model entry, as well as
the clinically meaningful confounders. Only the var-
iables that remained signiﬁcant at p value <0.05 were
included in the ﬁnal multivariate model in addition to
the clinically meaningful confounders.
The statistical signiﬁcance of change from baseline
in QOL measures at each follow-up visit was assessed
using a 1-sample Student t test compared to no change.
RESULTS
Between June 2, 2011, and December 22, 2011, 172
patients were enrolled in the study. The last follow-
up visit in the study occurred on January 31, 2013.
Subject disposition and accountability are provided
in Figure 1. Of 172 enrolled patients, 161 patients had
the investigational catheter inserted and comprised
the safety cohort. Radiofrequency ablation was per-
formed on 160 of the patients, and 38 of these pa-
tients were “roll-in” patients. The remaining 122
patients comprised the effectiveness cohort, which
consisted of enrolled patients who were ablated.
Five of 122 effectiveness cohort patients were lost to
follow-up before reaching the 12-month follow-up
visit. Patient characteristics are described in Table 1.
Average procedure time was 3.7  1.4 h, with
an average of 2.0  1.0 h ablation procedure time
(from the time of ﬁrst radiofrequency application to
the time of last application). Average ﬂuoroscopy
time per procedure was 41.5  26.0 min. Average
power applied during radiofrequency application was
31.1  4.1 W.
Per protocol, all index procedures (100.0%, 160
of 160) targeted the PVs. Of these procedures, 50.0%
(80 of 160) involved only PV isolation. The remaining
procedures (50%) included additional atrial targets:
41.2% only additional linear lesions, 1.9% only focal
non-PV targets, and 6.9% linear lesions and focal
non-PV targets. Cavotricuspid isthmus ablation was
performed in 19.4% (31 of 160) of the index procedures.
Based on the effectiveness cohort, KM analysis
shows that the probability of freedom from the per-
protocol effectiveness failure at 12 months post-
index procedure was 72.5% (95% CI: 64% to 80.5%;
transtelephonic compliance ¼ 83.9  17.21%). Thisincludes 2 subjects who were deemed failures because
new AADs were administered during the effectiv-
eness evaluation period. One subject had the drug
stopped on Day 104, and the second was given a new
AAD (a higher dose of metoprolol than the subject
previously took) at the 9-month visit. These 2 subjects
did not have recurrence after the initial procedure.
Because the lower bound of the 95% CI for this
KM graph is greater than the 50% pre-determined
performance criterion, the per-protocol effectiveness
outcome met the performance goal. In addition,
based on the effectiveness cohort, there were no
statistical differences in per-protocol primary effec-
tiveness between patients who received PV isolation,
only as compared to those who received additional
linear/foci targets.
For the effectiveness cohort, the probability of
freedom from symptomatic and all (symptomatic
or asymptomatic) atrial arrhythmia (AF/AFL/AT)
recurrence at 12-month follow-up visit were 74.0%
(95% CI: 66% to 82%) (Fig. 2) and 69.9% (95% CI: 62%
to 78%), respectively. The success rate after a single
ablation procedure and off drugs (Class I/III AAD)
at 12 months was 65.8% with a lower bound of the
95% CI of 56.5% (Table 2).
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FIGURE 2 Kaplan-Meier Curve of Time to First Atrial Fibrillation/Atrial Flutter/Atrial
Tachycardia Recurrence (Effectiveness Cohort, n ¼ 122)
Probability of freedom from symptomatic atrial arrhythmia recurrence at 12-month
follow-up visit.
TABLE 1 Baseline Patient Characteristics
Effectiveness
Cohort
(n ¼ 122)
Safety
Cohort
(n ¼ 161)
Age, yrs 58.3  10.93 58.7  10.83
Male 87 (71.3) 116 (72.0)
Patient history
AF duration, yrs 4.0 (1.4–7.1) 4.0 (1.5–7.5)
Atrial ﬂutter 37 (30.3) 52 (32.3)
Hypertension 74 (60.7) 96 (59.6)
Diabetes 14 (11.5) 20 (12.4)
Structural heart disease 15 (12.3) 19 (11.8)
Cerebrovascular accident/TIA 0 (0.0)/4 (3.3) 0 (0.0)/5 (3.1)
Prior thromboembolic events 6 (4.9) 10 (6.2)
NYHA functional class
None 101 (82.8) 133 (82.6)
I 15 (12.3) 18 (11.2)
II 5 (4.1) 8 (5.0)
Unknown 1 (0.8) 2 (1.2)
Failed antiarrhythmic drug class
I/III at baseline 62 (50.82) 79 (49.07)
II/IV only 17 (13.93) 24 (14.92)
Baseline antiarrhythmic medications
I/III taking at baseline 78 (63.93) 104 (64.60)
II/IV taking at baseline 59 (48.36) 81 (50.31)
Baseline QOL score
Mental component summary 49.2  11.2 49.7  11.1
Physical component summary 39.2  7.4 39.1  7.7
Symptom frequency score 20.8  10.3 21.1  10.8
Symptom severity score 16.9  8.7 17.2  8.8
LVEF, mm 60.3  7.8, 40/84 60.2  7.6, 40/84
LA dimension, mm 38.5  5.6, 26/50 38.5  5.7, 21/51
Values are mean  SD, n (%), median (interquartile range), or minimum/maximum.
LA ¼ left atrium; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association;
QOL ¼ quality of life; TIA ¼ transient ischemic attack.
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651The overall average CF recorded during a study
ablation procedure for all subjects undergoing abla-
tion (n ¼ 160) was 17.9  9.42 g. Figure 3 presents the
histogram distribution of the average CF used during
radiofrequency application with average CF shown in
5 g increments. The majority of procedures (efﬁcacy
cohort 68.8%, 77 of 112; safety cohort 68.1%, 96 of 141)
were completed with average CF between 10 and 25 g.
Based on their roll-in cases and experience as
the study progressed, investigators chose working
ranges for radiofrequency applications that varied
from 4 to 60 g. Working ranges of 5 to 40 g were
selected for 67.4% of all study procedures. Figure 4
presents the percentage of time investigators spent
in their selected ranges during radiofrequency appli-
cations by cohort. Overall, investigators remained in
their preselected working CF ranges 73.3  18.35%
of the time during radiofrequency application. Most
ablation procedures were conducted with the in-
vestigators working in their selected ranges 65% to
95% of the time.
Higher average CF during radiofrequency applica-
tion was not found to correlate with effectiveness.
KM analysis using the effectiveness cohort was per-
formed to compare the effectiveness outcome by
the investigators’ selected working ranges during
radiofrequency application $80% and <80%. As seen
in Figure 5, investigators working in their selected
ranges $80% of the time during radiofrequency ap-
plication demonstrated a signiﬁcant increase of 15%
in the effectiveness success at 12 months compared
with those working in their selected ranges <80%
of the time (81% vs. 66%, respectively; p ¼ 0.0440
[Wilcoxon test]).
Multivariate logistic regression analyses of risk
factors for the effectiveness outcome (Table 3)
showed that the percentage of time with CF within
investigator selected working ranges $80% during
therapy was signiﬁcantly associated with positive
effectiveness outcomes (p ¼ 0.0054; odds ratio:
4.25; 95% CI: 1.53 to 11.79), and longer procedure
time was negatively associated with effectiveness
outcome (p ¼ 0.0340; odds ratio: 0.99; 95% CI: 0.99
to 1.00).
Within the safety cohort (n ¼ 161), there were no
deaths, stroke, cerebrovascular accident, atrioeso-
phageal ﬁstula, myocardial infarction, thromboem-
bolism, or PV stenosis that occurred within the study
period. Procedure-related major adverse events
occurring within 7 days of the ablation procedure, as
adjudicated by an independent safety committee,
included: tamponade (n ¼ 4), pericarditis (n ¼ 3),
transient heart block (n ¼ 1, prior to radiofrequency
application), and 4 vascular access complications
TABLE 2 Success Rate After Single Ablation Procedure
and Off Drugs (Effectiveness Cohort)
Failure
Success
[95% Conﬁdence
Interval]
Cohort* 40 (34.2) 77 (65.8)
[56.7%–74.3%]
Reason for failure
AF recurrence post blanking 31 (26.5)
No AF recurrence post blanking 9 (7.7)
Repeat ablation 6 (5.1)
On Class I/III AAD at 12 months 4 (3.4)
Values are n (%). *The cohort (n ¼ 117) consists of 122 patients in the effectiveness
cohort minus the 5 patients who were lost to follow-up and were censored/
excluded from the analysis.
AAD ¼ antiarrhythmic drug; AF ¼ atrial ﬁbrillation.
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652(2 hematoma without intervention; 2 arteriovenous
ﬁstula requiring surgical repair).
The average CF was dichotomized at the median
of 14 g; 84.6% of procedure-related major adverse
events occurred among patients with CF $14 g (p ¼
0.0370). Multivariate logistic regression analysis
showed that average CF $14 g was not signiﬁcantly
correlated with procedure-related major adverse0
0
12 49 19 9 6 5
7713226118
9
9
2 1
13
Average CF per Ablation Procedure
0-
5.0
5.1
-10
.0
10
.1-
15.
0
15.
1-2
0.0
20
.1-
25
.0
25
.1-
30
.0
30
.1-
35
.0
35
.1-
40
.0
40
.1-
45
.0
>4
5.0
tion of Average CF
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rage CF shown in 5-g increments (effectiveness cohort, n ¼ 122;
1; data was unavailable or unanalyzable for 19 subjects).events. Further analyses including only adverse
events that are reasonably associated with radio-
frequency application (i.e., tamponade and peri-
carditis) showed that the correlation remained
insigniﬁcant in both univariate and multivariate
analyses.
The 4 tamponade cases all had a percentage of
time with CF $40 g >2.1% during radiofrequency
applications. Due to the limited number of tampo-
nade events, the correlation was only of borderline
signiﬁcance (p ¼ 0.0581).
Patients who underwent radiofrequency ablation
showed improved QOL in the mental and physical
components of the Short Form Health Survey Version
2 instrument irrespective of effectiveness outcome.
The mean mental and physical component scores
were signiﬁcantly higher at the 3-month follow-up
visit compared to baseline (7.2  9.89 [p < 0.0001]
and 2.6  6.74 [p < 0.0001], respectively). The
increased QOL scores remained relatively constant
through the 12-month follow-up visit (8.1  11.19
[p < 0.0001] and 3.5  6.74 [p < 0.0001], respectively).
Similarly, the mean symptom frequency and se-
verity scores were signiﬁcantly lower at the 3-month
follow-up compared to baseline (–10.5  10.27 [p <
0.0001] and –9.1  8.17 [p < 0.0001], respectively) and
remained relatively constant through the 12-month
follow-up visit (–10.0  9.84 [p < 0.0001] and –8.2
 8.30 [p < 0.0001], respectively).
DISCUSSION
The SMART-AF trial was the ﬁrst prospective, multi-
center clinical trial conducted to evaluate the safety
and effectiveness of an irrigated CF-sensing catheter
in patients with drug-refractory PAF. The 12-month
effectiveness success rate (freedom from symptom-
atic atrial arrhythmia recurrence) was 74%. There
were no unanticipated device-related adverse events.
The contribution of real-time CF sensing to the abla-
tion outcome was demonstrated by the signiﬁcantly
higher success rate (probability of freedom from
recurrence of 81% vs. 66%) in patients where the
investigators stayed within their selected CF range
$80% of the time during radiofrequency application,
suggesting that consistent and stable catheter-tissue
contact is necessary for effective ablation results.
In addition, these outcomes are accompanied by
clinically meaningful improvement in QOL and AF
symptoms/severity. Nevertheless, this is the ﬁrst
study of its kind, and the results will need to be
conﬁrmed in future randomized, controlled trial
against traditional non–CF-sensing irrigated catheters
(Central Illustration).
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Percentage of time investigators spent in their selected ranges during radiofrequency applications (effectiveness cohort, n ¼ 122; safety cohort,
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Investigators working in their selected ranges $80% of the time during radiofrequency
application demonstrated a signiﬁcant increase of 15% in the effectiveness success at 12
months compared to those working in their selected ranges <80% of the time
(effectiveness cohort, n ¼ 122).
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653In this study, even with a rigorous deﬁnition of
per-protocol effectiveness endpoint, the ablation
outcome appears to be higher than previously re-
ported in the study with similar patient population
and study protocol using the traditional ThermoCool
Catheter without CF (KM analysis 72.5% [current
study, included symptomatic AF/AT/AFL recur-
rences] vs. 66% [traditional ThermoCool Catheter
study, included symptomatic AF recurrence only],
respectively) (12). However, a direct comparison was
not conducted. In addition, a recent meta-analysis
reported that the single-procedure success rate
for PAF ablation was 66.6% (95% CI: 58.2% to
74.2%) (13). This meta-analysis included on- or
off-drug success rates per individual study deﬁni-
tion. In comparison, the single-procedure success rate
off drug in our study was 65.8%, and slightly higher at
68.4% if including off- or on-drug patients.
These data strongly support the notion that
real-time CF sensing is important in optimization
of long-term ablation outcomes. This aligns with a
recent publication showing that operators who abla-
ted with real-time CF data available had lower acute
PV reconnection rates than operators blinded to the
CF information (14). PV reconnection has been shown
to be an important factor contributing to mid- and
long-term recurrence (15,16). In a long-term study,
94% of the patients who underwent a second abla-
tion procedure had recovered PV conduction (16).In our study, repeat ablation procedures without
recurrence during the effectiveness period was
approximately 5% (6 of 122), which is substantially
lower in comparison to the 20% to 40% reported in the
expert consensus statement (1). Taken together, it is
conceivable that real-time visualization of CF during
radiofrequency applications reduces PV reconnection
TABLE 3 Multivariate Logistic Regression Analyses of Risk Factors for
Primary Effectiveness Endpoint (Effectiveness Cohort, n ¼122)
Risk Factor
Odds
Ratio
95% Conﬁdence
Interval p Value*
Total procedure time, min 0.99 0.99–1.00 0.0340
Percentage of time with CF within
investigator selected ranges $80%
4.25 1.53–11.79 0.0054
Percentage of time with lateral CF >30 g 1.16 0.94–1.42 0.1670
Percentage of time with shaft proximity
interference severity $2
0.99 0.97–1.01 0.3797
*Analysis was based on subjects with nonmissing data for outcomes and risk factors.
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654by creation of durable lesions, leading to fewer repeat
procedures and improved success rate, without
compromising the safety proﬁle or prolonging the
procedure time. However, this remains to be proven.
A recent study using a different CF-sensing catheter
system found that AF patients ablated with >20 g
average CF had lower recurrence at 12-month follow-
up (5). Although the overall average procedural CF
during radiofrequency application in our study was
found to be similar to that reported using the alter-
native CF-sensing catheter (6) (17.9  9.42 g vs. 17.2 
13.5 g, respectively), our data did not indicate a cor-
relation between higher average procedural CF and
effectiveness outcomes. The difference may be due to
a larger study population, different catheter design,
and user instructions, as well as an increased number
of operators with unique techniques in our study.
More importantly, our study operators were never
blinded to the CF at any time during the procedure.
Therefore, direct comparison of CF data from our
study to the previous study may be difﬁcult.
Another interesting ﬁnding of our study shows
that the percentage of time the investigator stayed51
57
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).within their selected working range (regardless of the
range selected) correlated positively with primary
effectiveness success. Speciﬁcally, multivariate ana-
lyses showed that investigators who stayed within
their selected ranges $80% during radiofrequency
application were approximately 4.25 times more
likely to have effectiveness success at 12 months
compared with those who did not (95% CI: 1.53 to
11.79). These data suggest that maintaining catheter-
tissue contact stability by maintaining the CF within
user selected range during ablation therapy increases
the likelihood that the radiofrequency power will be
effectively deposited within the tissue and not the
surrounding blood pool, and this in turn, could be
critical to achieving long-term success.
Our study demonstrates an acceptable safety pro-
ﬁle of AF ablation with the irrigated CF-sensing
catheter. Notably, there were no deaths, stroke,
cerebrovascular accident, atrioesophageal ﬁstula,
myocardial infarction, thromboembolism, or PV ste-
nosis within the study period. The cardiac tamponade
rate (2.48%) fell within the typical range published
in the literature (1,17,18). Among AF ablation re-
ports reviewed for the 2012 Heart Rhythm Society/
European Heart Rhythm Association/European Car-
diac Arrhythmia Society Expert Consensus State-
ment, cardiac tamponade had an incidence of up to
6% (1). Cappato et al. (17) reported tamponade rates of
1.2% (2005) (18) and 1.3% (2010) in 2 worldwide sur-
veys of AF procedures. Another large series reported
cardiac tamponade during 15 of 632 ablation pro-
cedures (2.4%) (19). In this study, there was a trend
toward greater percentage of time in higher CF
($40 g) for all the tamponade cases, but the correla-
tion was not statistically signiﬁcant, likely due to the
limited number of events reported.
It has been suggested that visualization of the
applied CF or catheter-tissue contact during the
ablation procedure could help reduce occurrence of
certain ablation complications without loss of lesion
effectiveness (7). In our study, average CF $14 g was
not signiﬁcantly correlated with procedure-related
major adverse events in the ﬁnal multivariate anal-
ysis. Further studies with a larger sample size would
allow us to better understand the correlation of CF
with safety outcomes.
Durable long-term effectiveness is the ultimate
goal of AF catheter ablation. A recent study found
that long-term recurrences in patients who received
AF ablation were common, even among those
who were arrhythmia free at 1-year post-ablation, and
that early recurrences were the strongest predictor
of late recurrences (20). These ﬁndings highlight the
need to improve lesion formation and consistency
PERSPECTIVES
CLINICAL COMPETENCY IN PATIENT CARE: Atrial ﬁbrilla-
tion (AF) ablation is more effective than antiarrhythmic drug
therapy in maintaining normal sinus rhythm in patients with
paroxysmal AF.
COMPETENCY IN PROCEDURAL SKILLS: A contact force
sensing catheter helps obtain stable catheter-to-cardiac tissue
contact during AF ablation, substantially improving 12-month
freedom from AF recurrence.
TRANSLATIONAL OUTLOOK 1: The mechanism of improved
outcomes derived from contact force sensing catheters for AF
ablation, and speciﬁcally the interaction between contact force,
catheter stability, duration and efﬁcacy of ablation needs further
examination to facilitate the further reﬁnement of ablation
apparatus.
TRANSLATIONAL OUTLOOK 2: A longer term study
including a wider variety of patients with AF is needed to conﬁrm
and assess the generalizability of the ﬁndings of this study.
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655to reduce PV reconnection. It has been known that
low electrode-tissue CF is associated with ineffective
lesion formation (7). Our study provided the ﬁrst clin-
ical outcomes of AF ablation using this CF-sensing
catheter, which showed a good medium-term success
without compromising the safety proﬁle.
STUDY LIMITATIONS. This 1-arm, open-label study
compared safety and effectiveness endpoints with
historical performance goals. No control group was
assessed. The analysis of clinical outcome as a func-
tion of how often the force stayed within the pre-
scribed interval was a post-hoc analysis, and should
be considered hypothesis-generating only. Because
the force-power-time index and lesion depth were
not measured, the exact mechanism of improved
success rate through maintaining stable CF warrants
further research. Patients with signiﬁcant left ven-
tricular dysfunction, more persistent forms of AF, and
advanced degrees of heart failure were excluded from
the study, meaning our results may not be extrapo-
lated to these populations. In the logistic regression
models, forward selection method was used to select
potential predictors for the outcomes. Given the low
event rates compared with the number of covariates
entered into the forward selection procedure, these
analyses should be regarded as exploratory and
considered hypotheses generating for follow-up
studies.
CONCLUSIONS
The SMART-AF study demonstrates that ablation
with a novel CF-sensing catheter is safe and effective
for the treatment of drug refractory symptomatic
PAF with clinically meaningful improvement in QOL
and symptom severity/frequency, and no unantici-
pated device-related adverse events. Stable CF during
radiofrequency application increases the probabil-
ity of a successful procedure outcome. Investigators
spending $80% of their radiofrequency ablation time
in their user-selected CF ranges were approximately
4.25 times more likely to have primary effectiveness
success at 12 months compared with those subjectswith CF <80% of the time within the selected ranges.
However, average CF during the procedure was not
found to correlate with increased procedural success
and procedure-related serious adverse events, such
as cardiac tamponade.
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